Edward van Wezel
Edward van Wezel is managing partner and founder of BioGeneration Ventures. Edward has extensive international expertise in small and large pharma and biotech companies. Edward currently serves on the the boards of Progentix Orthobiology, Synaffix, Cristal Therapeutics, Escalier Biosciences and Scenic Biotech. He previously served on the board of BioCeros (sold in 2011), NovioGendix (sold in 2015) and of Acerta Pharma (sold in 2016). Edward started his industrial career as process engineer for Chiron Inc. and working for Johnson & Johnson as project manager. At J&J he was responsible for preclinical and Phase II product development projects in the oncology franchise. In addition he was involved in in-licensing activities. Since 2000 he gained experience in several small start-up and early stage companies in the Netherlands. He was director business development at Pepscan Systems and managing director of Macrozyme. Edward holds a M.Sc in chemistry from the University of Utrecht and a M.Sc in biochemical engineering from the Delft University of Technology.